The Effect of rebamipide as adjunct therapy with proton-pump inhibitor in patients with upper gastrointestinal bleeding : a retrospective study / Julius M. Ador and Roy Caballero.

Includes bibliographical references.

ABSTRACT: Rebamipide, as a gastroprotective agent, is currently not included in the treatment recommendations of Upper Gastrointestinal Bleeding (UGIB). This retrospective cohort study determined the effect of Rebamipide as adjunct therapy with Proton-pump Inhibitor (PPI) in patients with UGIB admitted in FEU-NRMF Medical Foundation. A clear review was conducted within 5 years duration. Patients were divided into two groups: PPI alone vs. PPI + Rebamipide. 390 patients/cases were included in this study: 149 PPI alone cases and 241 PPI +Rebamipide cases. Resolution of signs of bleeding as to hematemesis, melena or hematochezia within 5 days duration was noted, as well as, the specific duration/time of resolution of signs of bleeding. Among 149 cases with PPI alone, 14.09% (21 cases) had resolution of signs within 5 days; while among those 241 cases with PPi + Rebamipide, the rate of resolution was 93% (224 cases). The rate difference was statistically significant wherein the resolution of signs of bleeding was significant association with PPI + Rebamipide intervention (p<0.001). In addition, the average time of resolution of the PPi alone group was 4.00 days +/-1.22, median days 4, and within an absolute range of 2-6 days resolution. On the other hand, the PPI + Remabipide group had average resolution time of 3.09 days +/ -0.95, with median days of 3, and within the absolute range of 2-5 days. In conclusion, Rebamipide + PPI is more effective than PPI alone in the treatment of UGIB. Also, Rebamipide may be an effective adjunct therapy with PPI in shortening the duration of UGIB.

Research - Department of Medicine